Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, G.
Right arrow Articles by McLeod, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, G.
Right arrow Articles by McLeod, H. L.
Clinical Cancer Research Vol. 8, 2605-2611, August 2002
© 2002 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Human Carboxylesterase 2 Is Commonly Expressed in Tumor Tissue and Is Correlated with Activation of Irinotecan1

Guang Xu2, Wanghai Zhang2, Margaret K. Ma and Howard L. McLeod3

Departments of Medicine, Molecular Biology and Pharmacology, and Genetics, Washington University School of Medicine, and The Siteman Cancer Center, St. Louis, Missouri 63110

The prodrug irinotecan is an active agent for the treatment of advanced colorectal cancer and a number of other solid tumors. Irinotecan is converted in vivo to SN-38 (7-ethyl-10-hydroxy-camptothecin), the active metabolite that causes cell death, by human liver carboxylesterases. Previous studies suggest that human carboxylesterase 2 (CES2) is the key activating isoform. Although conversion of irinotecan to SN-38 by liver carboxylesterase is an inefficient process, clinical data indicate that irinotecan has significant antitumor activity. This scenario raises the possibility that local conversion of irinotecan to SN-38 by CES2 in tumor tissues might occur. The expression profile of CES2 protein in human tumor tissues was evaluated in a tissue array of 18 different types of human cancer and in a panel of normal human liver samples by immunohistochemistry and Western blot, respectively. Cytosolic CES2 expression was observed in 101 of 154 tumors (66%) and 55 of 60 normal tissues (92%). Among the 18 types of tumors analyzed, 2 types (gallbladder tumor and lymphoma) did not express CES2, 5 types expressed weak CES2, and 11 types expressed moderate to intense CES2. In functional studies, CES2 protein was highly variable among liver samples, with a 15-fold range in cytosol and a 3-fold range in microsome fractions. Liver microsomal CES2 protein expression was significantly correlated with irinotecan activation to SN-38 (Rs = 0.70; P = 0.007). This study confirms that CES2 is a key enzyme for irinotecan activation. Tumor CES2 expression may contribute to variable response to irinotecan chemotherapy for solid tumors.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. M. Hoskins, E. Marcuello, A. Altes, S. Marsh, T. Maxwell, D. J. Van Booven, L. Pare, R. Culverhouse, H. L. McLeod, and M. Baiget
Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes
Clin. Cancer Res., March 15, 2008; 14(6): 1788 - 1796.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. A. Schiel, S.-l. Green, W. I. Davis, P. C. Sanghani, W. F. Bosron, and S. P. Sanghani
Expression and Characterization of a Human Carboxylesterase 2 Splice Variant
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 94 - 101.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S.-R. Kim, K. Sai, T. Tanaka-Kagawa, H. Jinno, S. Ozawa, N. Kaniwa, Y. Saito, A. Akasawa, K. Matsumoto, H. Saito, et al.
Haplotypes and a Novel Defective Allele of CES2 Found in a Japanese Population
Drug Metab. Dispos., October 1, 2007; 35(10): 1865 - 1872.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Imai, M. Taketani, M. Shii, M. Hosokawa, and K. Chiba
Substrate Specificity of Carboxylesterase Isozymes and Their Contribution to Hydrolase Activity in Human Liver and Small Intestine
Drug Metab. Dispos., October 1, 2006; 34(10): 1734 - 1741.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. D. Hunter, J. K. Thurlow, J. Fleming, P. J.H. Drake, J. K. Vass, G. Kalna, D. J. Higham, P. Herzyk, D. G. MacDonald, E. K. Parkinson, et al.
Divergent routes to oral cancer.
Cancer Res., August 1, 2006; 66(15): 7405 - 7413.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. C. Drummond, C. O. Noble, Z. Guo, K. Hong, J. W. Park, and D. B. Kirpotin
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
Cancer Res., March 15, 2006; 66(6): 3271 - 3277.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-F. Gagnon, O. Bernard, L. Villeneuve, B. Tetu, and C. Guillemette
Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer
Clin. Cancer Res., March 15, 2006; 12(6): 1850 - 1858.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Chowbay, S. R. Jada, and D. L. Wan Teck
Correspondence re: Cecchin et al., Carboxylesterase Isoform 2 mRNA Expression in Peripheral Blood Mononuclear Cells Is a Predictive Marker of the Irinotecan to SN38 Activation Step in Colorectal Cancer Patients. Clin Cancer Res 2005;11:6901-7.
Clin. Cancer Res., March 15, 2006; 12(6): 1942 - 1942.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Cecchin, G. Corona, and G. Toffoli
Reply to the Letter to the Editor from Chowbay et al
Clin. Cancer Res., March 15, 2006; 12(6): 1942 - 1942.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Gomez-Manzano, M. M. Alonso, W.K. A. Yung, F. McCormick, D. T. Curiel, F. F. Lang, H. Jiang, B. N. Bekele, X. Zhou, R. Alemany, et al.
Delta-24 Increases the Expression and Activity of Topoisomerase I and Enhances the Antiglioma Effect of Irinotecan
Clin. Cancer Res., January 15, 2006; 12(2): 556 - 562.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Kubo, S.-R. Kim, K. Sai, Y. Saito, T. Nakajima, K. Matsumoto, H. Saito, K. Shirao, N. Yamamoto, H. Minami, et al.
FUNCTIONAL CHARACTERIZATION OF THREE NATURALLY OCCURRING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE CES2 GENE ENCODING CARBOXYLESTERASE 2 (HCE-2)
Drug Metab. Dispos., October 1, 2005; 33(10): 1482 - 1487.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Cecchin, G. Corona, S. Masier, P. Biason, G. Cattarossi, S. Frustaci, A. Buonadonna, A. Colussi, and G. Toffoli
Carboxylesterase Isoform 2 mRNA Expression in Peripheral Blood Mononuclear Cells Is a Predictive Marker of the Irinotecan to SN38 Activation Step in Colorectal Cancer Patients
Clin. Cancer Res., October 1, 2005; 11(19): 6901 - 6907.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. G. Azrak, J. Yu, L. Pendyala, P. F. Smith, S. Cao, X. Li, W. D. Shannon, F. A. Durrani, H. L. McLeod, and Y. M. Rustum
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors
Mol. Cancer Ther., May 1, 2005; 4(5): 843 - 854.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Michael and M.M. Doherty
Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy
J. Clin. Oncol., January 1, 2005; 23(1): 205 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Bhattacharya, K. Toth, R. Mazurchuk, J. A. Spernyak, H. K. Slocum, L. Pendyala, R. Azrak, S. Cao, F. A. Durrani, and Y. M. Rustum
Lack of Microvessels in Well-Differentiated Regions of Human Head and Neck Squamous Cell Carcinoma A253 Associated with Functional Magnetic Resonance Imaging Detectable Hypoxia, Limited Drug Delivery, and Resistance to Irinotecan Therapy
Clin. Cancer Res., December 1, 2004; 10(23): 8005 - 8017.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. H. J. Mathijssen, F. A. de Jong, R. H. N. van Schaik, E. R. Lepper, L. E. Friberg, T. Rietveld, P. de Bruijn, W. J. Graveland, W. D. Figg, J. Verweij, et al.
Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes
J Natl Cancer Inst, November 3, 2004; 96(21): 1585 - 1592.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Tabata, M. Katoh, S. Tokudome, M. Nakajima, and T. Yokoi
IDENTIFICATION OF THE CYTOSOLIC CARBOXYLESTERASE CATALYZING THE 5'-DEOXY-5-FLUOROCYTIDINE FORMATION FROM CAPECITABINE IN HUMAN LIVER
Drug Metab. Dispos., October 1, 2004; 32(10): 1103 - 1110.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Tabata, M. Katoh, S. Tokudome, M. Hosakawa, K. Chiba, M. Nakajima, and T. Yokoi
BIOACTIVATION OF CAPECITABINE IN HUMAN LIVER: INVOLVEMENT OF THE CYTOSOLIC ENZYME ON 5'-DEOXY-5-FLUOROCYTIDINE FORMATION
Drug Metab. Dispos., July 1, 2004; 32(7): 762 - 767.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. L. McLeod and J. W. Watters
Irinotecan Pharmacogenetics: Is It Time to Intervene?
J. Clin. Oncol., April 15, 2004; 22(8): 1356 - 1359.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. G. Azrak, S. Cao, H. K. Slocum, K. Toth, F. A. Durrani, M.-b. Yin, L. Pendyala, W. Zhang, H. L. McLeod, and Y. M. Rustum
Therapeutic Synergy Between Irinotecan and 5-Fluorouracil against Human Tumor Xenografts
Clin. Cancer Res., February 1, 2004; 10(3): 1121 - 1129.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. P. Sanghani, S. K. Quinney, T. B. Fredenburg, Z. Sun, W. I. Davis, D. J. Murry, O. W. Cummings, D. E. Seitz, and W. F. Bosron
Carboxylesterases Expressed in Human Colon Tumor Tissue and Their Role in CPT-11 Hydrolysis
Clin. Cancer Res., October 15, 2003; 9(13): 4983 - 4991.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.